Apimeds Pharmaceuticals US, Inc.
APUS· NYSE
Who holds Apimeds Pharmaceuticals US, Inc., from the managers’ Form 13F reports for the quarter ended Sep 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Hemenway Trust Co LLC | 27.4K | −90.0% | $137K | 0.1% | Nov 12, 2026 |
| UBS Group AG | 6.4K | −45.6% | $32.1K | 0% | Nov 10, 2026 |
| Vanguard Capital Management LLC | 5.2K | −91.9% | $25.8K | 0% | Nov 13, 2026 |
| Vanguard Fiduciary Trust Co | 2.4K | −90.0% | $12K | 0% | Nov 13, 2026 |
| Tower Research Capital LLC (TRC) | 1.4K | −16.9% | $6.9K | 0.1% | Nov 16, 2026 |
| HRT Financial LP | 29.5K | New | $147 | 0.1% | Nov 13, 2026 |
| Ankerstar Wealth, LLC | 15 | New | $75 | 0.1% | Nov 13, 2026 |
| Citigroup Inc | 1 | New | $5 | 0% | Nov 4, 2026 |
| JPMorgan Chase & Co | 1 | New | $5 | 0% | Nov 12, 2026 |